Study details
Enrolling now
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT IDNCT06223542ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
95
Study length
about 1.1 years
Ages
18+
Locations
1 site in MD
About this study
This trial is testing the safety and best dose of a drug called TAK-243 in people with advanced cancer. TAK-243 is an inhibitor that may help stop cancer cells from growing and surviving.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take UAE Inhibitor TAK-243
- 2.Undergo Biopsy Procedure
- 3.Undergo Biospecimen Collection
- +3 more
PhasePhase 1
Primary goalMaximum tolerated dose (MTD)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Maximum tolerated dose (MTD), Recommended phase 2 dose
Secondary: Pharmacodynamic (PD) variables
Procedures
biopsy, diagnostic, imaging
Body systems
Oncology